December 9, 2009 (FinancialWire) — Genzyme Corp. (NASDAQ: GENZ) has named Robert J. Bertolini to the company’s board. Bertolini was executive vice president and chief financial officer at Schering-Plough Corp. until its recent merger with Merck & Co. (NYSE: MRK).

Bertolini had been with Schering-Plough since 2003, where he worked with the chief executive officer in various aspects of transforming the company’s operations.

Prior to joining Schering-Plough, Bertolini spent 20 years at PriceWaterhouseCoopers, where he held positions of increasing responsibility, ultimately leading the global pharmaceutical industry practice.

Genzyme is a biotechnology company that has more than 11,000 employees.

The company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279). Recently issued reports and/or recorded webcasts include Aria International Holdings, Inc. (OTCBB: ARAH), Continental Materials Corp. (AMEX: CUO), Darling International, Inc. (NYSE: DAR), Document Security Systems, Inc. (AMEX: DMC), and Juhl Wind, Inc. (OTCBB: JUHL).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.